Neo Ivy Capital Management’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.22M Buy
10,922
+8,200
+301% +$3.04M 0.97% 12
2026
Q1
$797K Buy
+2,722
New +$895K 0.21% 174
2025
Q2
– Sell
-6,104
Closed -$2.65M – 393
2025
Q1
$2.65M Buy
6,104
+5,129
+526% +$2.06M 0.85% 24
2024
Q4
$359K Buy
+975
New +$408K 0.07% 196
2023
Q4
$715K Buy
+1,516
New +$701K 1.6% 18
2023
Q3
– Sell
-6,411
Closed -$2.85M – 358
2023
Q2
$2.85M Buy
+6,411
New +$2.96M 1.5% 11
2022
Q1
– Sell
-19
Closed -$9K – 513
2021
Q4
$9K Sell
19
-579
-97% -$244K 0.01% 386
2021
Q3
$157K Sell
598
-85
-12% -$32.3K 0.18% 181
2021
Q2
$261K Buy
+683
New +$261K 0.26% 139
2020
Q3
– Sell
-598
Closed -$157K – 496
2020
Q2
$157K Sell
598
-219
-27% -$58.4K 0.18% 181
2020
Q1
$185K Buy
817
+801
+5,006% +$218K 0.3% 125
2019
Q4
$5K Buy
+16
New +$4.4K 0.01% 238
2019
Q2
– Sell
-1,639
Closed -$470K – 310
2019
Q1
$470K Buy
+1,639
New +$474K 0.27% 154

Other funds holding ELV

Neo Ivy Capital Management's ELV Position: Q2 2026 in Review

Neo Ivy Capital Management increased its Elevance Health (ELV) stake by 301% in Q2 2026, buying an estimated $3.04M and bringing the position to 10,922 shares worth $4.22M. The position accounts for 0.97% of the portfolio, ranked #12.

Neo Ivy Capital Management first reported a position in ELV in Q1 2019 and has held it in 13 quarters since. 1,610 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Neo Ivy Capital Management held 10,922 shares of Elevance Health worth $4.22M as of Q2 2026.
  • Neo Ivy Capital Management bought 8,200 Elevance Health shares in Q2 2026, an estimated $3.04M.
  • Elevance Health made up 0.97% of Neo Ivy Capital Management's portfolio in Q2 2026, its #12 holding.
  • Neo Ivy Capital Management first reported a position in Elevance Health in Q1 2019 and has held it in 13 quarters since.
  • 1,610 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.